# AstraZeneca Plc agreement to divest the prescription medicine rights to Nexium in Europe

- Link: https://www.directorstalkinterviews.com/astrazeneca-plc-agreement-to-divest-the-prescription-medicine-rights-to-nexium-in-europe/412760593
- Published: 2018-10-30T08:02:35+00:00
- Author: Charlotte Edwards

**[AstraZeneca Plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
announced the agreement to divest the prescription medicine rights to Nexium (esomeprazole)
in Europe, as well as the global rights (excluding the US and Japan) to Vimovo (
naproxen/esomeprazole) to Grünenthal. The medicines are outside AstraZeneca’s three
main therapy areas of Oncology, Cardiovascular, Renal & Metabolism and Respiratory.
Nexium has lost compound patent protection in the majority of global markets. Vimovo
is patent protected in most European markets until 2025.

Nexium, a proton pump inhibitor developed by AstraZeneca, helps to reduce the amount
of acid produced by the stomach in patients with gastrointestinal reflux conditions
and ulcers. It has a number of indications, including the prevention and treatment
of gastric ulcers induced by pain-relieving non-steroidal anti-inflammatory drugs(
NSAIDs).

Vimovo is a modified-release fixed-dose combination tablet of naproxen, a pain-relieving
NSAID and esomeprazole, the active ingredient in Nexium, for the treatment of various
inflammatory diseases, including osteoarthritis, rheumatoid arthritis and ankylosing
spondylitis in patients at risk of developing NSAID-associated gastric ulcers and/
or duodenal ulcers.

Mark Mallon, Executive Vice President, Global Product & Portfolio Strategy said:“
The divestment agreements allow us to realise value from our successful medicines
while redeploying our resources on developing innovative medicines for patients 
across our three main therapy areas, which we expect to drive growth for AstraZeneca.
Grünenthal is a science-based pharmaceutical company specialised in innovative pain
management and related therapies. Its expertise and distribution networks will help
expand the commercial potential of both Nexium and Vimovo, helping to reach many
patients who could benefit.”

**Financial considerations**

The divestment is expected to complete in 2018. For Nexium, Grünenthal will make
an upfront payment of $700 million upon completion. AstraZeneca may also receive
future milestones and sales-related payments of up to $90 million. For Vimovo, Grünenthal
will make an upfront payment of $115 million on completion. AstraZeneca may also
receive future milestones and sales-related payments of up to $17 million. Upfront
and milestone payments will be reported as Other Operating Income in the Company’s
financial statements.

AstraZeneca will continue to commercialise Nexium in all markets outside Europe,
where the Company retains the rights. On completion of the agreements, AstraZeneca
will not retain any ownership rights to Vimovo globally, or to Nexium in Europe.
Nexium sales in Europe in H1 2018 were $121million; Vimovo global sales excluding
the US and Japan in the same period were $37million. AstraZeneca will continue to
manufacture and supply Nexium under a long-term supply agreement.

**About Nexium**

Nexium (esomeprazole) is used to treat gastroesophageal reflux disease, ulcers, 
and Zollinger-Ellison syndrome. It is also used for the prevention and treatment
of gastric ulcers induced by pain-relieving NSAIDs. Nexium is available in several
formulations (Nexium gastro-resistant granules for oral suspension, Nexium gastro-
resistant Multi-Unit Pellet System (Nexium MUPS™) tablets, and Nexium injection/
infusion) with varying approved indications. The rights to over-the-counter Nexium
were externalised to Pfizer Consumer Health in 2012.

**About Vimovo**

Vimovo (naproxen/esomeprazole) modified-release tablet is a fixed-dose combination
of naproxen, a pain-relieving NSAID and esomeprazole, the active ingredient in Nexium.
It is indicated for the symptomatic treatment of osteoarthritis, rheumatoid arthritis
and ankylosing spondylitis in patients who are at risk of developing NSAID-associated
gastric ulcers and/or duodenal ulcers and where treatment with lower doses of naproxen
or of other NSAIDs is not considered sufficient. The rights to Vimovo in the United
States were externalised to Horizon Pharma in 2013.

**About AstraZeneca**

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the
discovery, development and commercialisation of prescription medicines, primarily
for the treatment of diseases in three therapy areas – Oncology, Cardiovascular,
Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and
its innovative medicines are used by millions of patients worldwide.

Share on: